Exploration of novel biomarker for the eligibility of neoadjuvant chemotherapy followed by operation for the patient with biliary pancreatic cancer

Exploration of novel biomarker for the eligibility of neoadjuvant chemotherapy followed by operation for the patient with biliary pancreatic cancer - Biliary-pancreatic cancer preoperative treatment outcome biomarker exploration study: B-PROBE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058615

Enrollment

100

Registered

2025-07-28

Start date

2020-04-22

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer,bile duct cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients must (1) be of any sex, (2) be at least 20 years old at the time of consent, and (3) have received a full explanation of the study, understood its content, and voluntarily signed a written informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria include: (1) ECOG Performance Status of 3 or 4, (2) diagnosis of dementia, and (3) any case in which the investigator or sub-investigator determines the patient to be inappropriate for study enrollment.

Design outcomes

Primary

Measure	Time frame
To investigate the associations between drug-related, tumor-related, and host-related factors and the therapeutic response to multimodal treatment.	—

Countries

Japan

Contacts

Public ContactMasao Nakajima

Yamaguchi university graduate school of medicine Department of Gastroenterological, Breast and Endocrine Surgery

geka2dm@yamaguchi-u.ac.jp0836222264

Outcome results